Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes.
acute myeloid leukemia
outcome
prognosis
risk classification system
survival
Journal
Therapeutic advances in hematology
ISSN: 2040-6207
Titre abrégé: Ther Adv Hematol
Pays: England
ID NLM: 101549589
Informations de publication
Date de publication:
2020
2020
Historique:
received:
08
07
2020
accepted:
23
09
2020
entrez:
21
12
2020
pubmed:
22
12
2020
medline:
22
12
2020
Statut:
epublish
Résumé
5-azacytidine (5-AZA) improves survival of patients with higher-risk myelodysplastic syndromes (MDSs) and oligoblastic acute myeloid leukemia (AML); however, predictive factors for response and outcome have not been consistently studied. This study of the Hellenic MDS Study Group included 687 consecutive patients with higher-risk MDS and oligoblastic AML treated with 5-AZA. The International Prognostic Scoring System (IPSS) revised version (IPSS-R), Eastern Cooperative Oncology Group Performance Status (ECOG PS) (0 or 1 ECOG PS and SF levels > 520 ng/ml independently predict response to 5-AZA, OS and LFS. Their incorporation in the IPSS and IPSS-R scores enhances these scores' predictive power in 5-AZA-treated higher-risk MDS and oligoblastic AML patients.
Sections du résumé
BACKGROUND
BACKGROUND
5-azacytidine (5-AZA) improves survival of patients with higher-risk myelodysplastic syndromes (MDSs) and oligoblastic acute myeloid leukemia (AML); however, predictive factors for response and outcome have not been consistently studied.
METHODS
METHODS
This study of the Hellenic MDS Study Group included 687 consecutive patients with higher-risk MDS and oligoblastic AML treated with 5-AZA.
RESULTS
RESULTS
The International Prognostic Scoring System (IPSS) revised version (IPSS-R), Eastern Cooperative Oncology Group Performance Status (ECOG PS) (0 or 1
CONCLUSIONS
CONCLUSIONS
ECOG PS and SF levels > 520 ng/ml independently predict response to 5-AZA, OS and LFS. Their incorporation in the IPSS and IPSS-R scores enhances these scores' predictive power in 5-AZA-treated higher-risk MDS and oligoblastic AML patients.
Identifiants
pubmed: 33343854
doi: 10.1177/2040620720966121
pii: 10.1177_2040620720966121
pmc: PMC7727043
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2040620720966121Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
Exp Hematol. 2018 Sep;65:34-37
pubmed: 29883686
Br J Haematol. 2011 Dec;155(5):599-606
pubmed: 21981697
Blood. 2017 Mar 30;129(13):1753-1762
pubmed: 28096091
Leuk Res. 2014 May;38(5):545-50
pubmed: 24598841
Blood. 2012 Dec 13;120(25):5084-5
pubmed: 23243156
Blood. 2011 Jan 13;117(2):403-11
pubmed: 20940414
Leuk Res. 2014 Jan;38(1):57-64
pubmed: 24238640
Ann Hematol. 2013 Oct;92(10):1413-4
pubmed: 23512104
Blood. 2006 Jul 15;108(2):419-25
pubmed: 16609072
Stat Med. 1994 Aug 30;13(16):1619-34
pubmed: 7973238
Int J Hematol. 2012 May;95(5):527-34
pubmed: 22407873
Lancet Oncol. 2009 Mar;10(3):223-32
pubmed: 19230772
Am J Hematol. 2018 Jan;93(1):129-147
pubmed: 29214694
Int J Hematol. 2019 Nov;110(5):533-542
pubmed: 31359362
Haematologica. 2018 Oct;103(10):1627-1634
pubmed: 29903757
Blood. 2018 Dec 20;132(25):2629-2638
pubmed: 30305280
Leuk Res. 2012 Nov;36(11):1370-5
pubmed: 22917770
Eur J Clin Invest. 2013 Nov;43(11):1120-8
pubmed: 24102333
Am J Hematol. 2013 Jul;88(7):566-70
pubmed: 23605934
Acta Haematol. 2014;131(4):231-8
pubmed: 24335346
Blood. 2012 Sep 20;120(12):2454-65
pubmed: 22740453
Hematology. 2016 Jan;21(1):34-41
pubmed: 26218077
Leukemia. 2016 Mar;30(3):649-57
pubmed: 26464171
Blood. 2014 Feb 6;123(6):829-36
pubmed: 24363399
Ann Hematol. 2013 Dec;92(12):1617-23
pubmed: 23842708
Blood. 2019 Jan 3;133(1):7-17
pubmed: 30361262
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Leuk Res. 2014 Jul;38(7):744-50
pubmed: 24795069
Leuk Lymphoma. 2019 Jul;60(7):1721-1730
pubmed: 30424699
Blood. 1997 Mar 15;89(6):2079-88
pubmed: 9058730
Eur J Haematol. 2018 Dec;101(6):766-773
pubmed: 30091166